

- **Name:** Junji Furuse
Professor,
 - **Current Position & Affiliation:** Department of Medical Oncology,
Kyorin University Faculty of Medicine
 - **Country:** Japan
-

• Educational Background:

July, 1992 Ph.D. Chiba University School of Medicine
March, 1984 M.D. Chiba University School of Medicine

Postgraduate Training

1987-1991 Fellowship, Department of the First Internal Medicine, Chiba University School of Medicine

1984-1987 Residency, Internal Medicine, Chiba University School of Medicine

• Professional Experience:

In 1984, graduated from Chiba University of Medical School and then attended the First Department of Internal Medicine, Chiba University.

July 1992- February 2008: Division of Hepatobiliary Pancreatic Medical Oncology, National Cancer Center Hospital East

• Professional Organizations:

March 2008-: Professor, Department of Medical Oncology, Kyorin University Faculty of Medicine.

April. 2008-:

Chair of Hepatobiliary and Pancreatic Oncology Group of Japanese Clinical Oncology Group (JCOG)

• Main Scientific Publications:2018-2020

1. Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N. Surgery for pancreatic neuroendocrine tumor G3 and carcinoma G3 should be considered separately. Ann Surg Oncol 2019;26(5):1385-1393.
2. Kitamura H, Nagashima F, Andou M, Furuse J. Feasibility of Continuous Geriatric Assessments as a Prognostic Indicator in Elderly People with Gastrointestinal Cancer. Intern Med. 2020;59(1):15-22.
3. Okusaka T, Nakamura M, Yoshida M, Kitano M, Uesaka K, Ito Y, Furuse J,

- Hanada K, Okazaki K; Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society. Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. *Pancreas*. 2020;49(3):326-335.
4. Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. *J Gastroenterol*. 2020;55(4):369-382.
 5. Okano N, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H, Furuse J. First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. *Invest New Drugs*. 2020 Mar 20. doi: 10.1007/s10637-020-00924-3. [Epub ahead of print]
 6. Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. *J Gastroenterol*. 2020 Feb 27. doi: 10.1007/s00535-020-01668-w. [Epub ahead of print]
 7. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. *Gut*. 2019 Dec 4. pii: gutjnl-2019-318934. doi: 10.1136/gutjnl-2019-318934. [Epub ahead of print]
 8. Okuyama H, Ikeda M, Okusaka T, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Hara H, Murohisa G, Shioji K, Asagi A, Mizuno N, Kojima M, Yamanaka T, Furuse J. A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). *Neuroendocrinology*. 2020 Jan 2. doi: 10.1159/000505550. [Epub ahead of print]
 9. Koyama T, Shimizu T, Iwasa S, Fujiwara Y, Kondo S, Kitano S, Yonemori K, Shimomura A, Iizumi S, Sasaki T, Furuse J, Yamamoto N. First-in-human phase I study of E7090, a novel selective FGFR inhibitor, in patients with advanced solid tumors. *Cancer Sci*. 2019 Dec 2. doi: 10.1111/cas.14265. [Epub ahead of print]
 10. Yamamoto N, Ryoo BY, Keam B, Kudo M, Lin CC, Kunieda F, Ball HA, Moran D, Komatsu K, Takeda K, Fukuda M, Furuse J, Morita S, Doi T. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies. *Invest New Drugs* 2019 Apr 30. doi: 10.1007/s10637-019-00780-w. [Epub ahead of print]